Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

Cepheid licences Quantovir’s HPV portfolio

Cepheid : 25 September, 2007  (New Product)
Cepheid has entered into an agreement to exclusively licence the Human Papillomavirus (HPV) patent portfolio held by Quantovir of Sweden for the quantitative measurement of high-risk HPV types using DNA-based detection.
Quantovir is believed to be the first to demonstrate that a molecular diagnostic test measuring the quantity, or viral load, of HPV DNA present in cervical specimens can be used to predict a woman's risk of developing cervical cancer. Cepheid plans to utilise Quantovir's technology to develop a new type of HPV test for the GeneXpert System.

'The GeneXpert System is ideal for the rapid diagnosis of infectious organisms like Methicillin-resistant Staphylococcus aureus (MRSA), but it can also be used to generate actionable, treatment-determining results in other medical areas including oncology and pharmaocogenetics,' said John L Bishop, CEO of Cepheid. 'With the GeneXpert System, molecular diagnostics is no longer reserved solely for the highly complex laboratory setting; it is also enabling the benefits of this technology to be realised in moderately complex settings. An HPV test for the GeneXpert System is expected to provide accurate PCR results in minutes rather than days in a variety of clinical settings.'

Given the demonstrated correlation of the presence of HPV with cervical cancer, HPV DNA testing has become an important diagnostic determinant of cancer risk. However, current tests approved by the US Food and Drug Administration do not measure sample adequacy, and thus cannot accurately quantitate HPV viral load.

Cepheid's potential HPV test for the GeneXpert System is designed to measure HPV viral load, which may help to identify patients most at risk.

'It is gratifying to see our research leading to the possible discovery of disease at a much earlier stage,' said Professor Ulf Gyllensten of the Rudbeck Laboratory in Uppsala, Sweden. 'Early detection delivers greater opportunities for improving patient outcomes.'

Current recommendations state that HPV DNA testing may be used in conjunction with a Pap in women over 30, to follow patients with previous positive high-risk HPV screening results, or when Pap results are uncertain. Analysts have estimated the current domestic market for diagnostic preventative testing at approximately $600-700 million.
Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo